For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Orange: Orange announces the signing of a binding agreement with Lorca to acquire their 50% stake in MasOrange Press releaseParis, 12 December 2025 Orange announces the signing of a binding agreement with Lorca to acquire their 50% stake in MasOrange Orange has signed a binding agreement with Lorca to acquire full ownership of MasOrange, Spain’s leading operator in terms of customer base, through the acquisition of the remaining 50% stake in its Spanish joint venture for a price of 4.25 billion euros in cash. This announcement confirms the that was previously announced on 31 October. Th...
Orange : Orange annonce la signature d’un accord engageant avec Lorca pour acquérir sa participation de 50 % dans MasOrange Communiqué de presseParis, le 12 décembre 2025 Orange annonce la signature d’un accord engageant avec Lorca pour acquérir sa participation de 50 % dans MasOrange Orange a signé un accord engageant avec Lorca en vue d’acquérir l’intégralité de MasOrange, premier opérateur sur le marché espagnol en nombre de clients. A travers cette accord, Orange acquerra les 50 % du capital détenu par son coactionnaire pour un prix de 4,25 milliards d’euros en numéraire. Cette anno...
Novartis breaks ground on flagship manufacturing hub in North Carolina FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US at scaleGroundbreaking marks continuation of Novartis investment and growth in the US, capping year of significant regulatory and manufacturing milestones East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company...
Total number of shares and voting rights at November 30, 2025 4 December 2025 Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years. DateNumber of shar...
Nombre d'actions et de droits de vote au 30 novembre 2025 4 décembre 2025 Orange : Information relative au nombre total d’actions et de droits de vote prévue par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers En application de l’article L. 22-10-46 du Code de commerce, il est automatiquement conféré, à compter du 3 avril 2016, un droit de vote double aux actions entièrement libérées inscrites au nominatif depuis deux ans au nom d’un même actionnaire. DateNombre d’actions composant le capitalNombre d’actions auto-déte...
A director at SLB Ltd sold 5,500 shares at 35.820USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.